{
    "clinical_study": {
        "@rank": "85886", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "Naltrexone plus Sertraline"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Experimental", 
                "description": "Naltrexone alone"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in\n      Alaska natives with alcohol dependence.  The study will also examine whether a combination\n      of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used\n      alone.  Alaska Native individuals will be recruited into a 16 week outpatient study."
        }, 
        "brief_title": "Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)", 
        "completion_date": {
            "#text": "November 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "Alcoholism", 
            "Alcohol Dependence"
        ], 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Alaska Native having biological Alaska Native ancestry.\n\n          -  Meets criteria for alcohol dependence.\n\n          -  Prior to entering the study must be abstinent between 3 and 14 days and have a\n             withdrawal assessment.\n\n          -  Stable residence to ensure that subjects can be located during the study.\n\n        Exclusion Criteria:\n\n          -  Currently meets criteria for abuse or dependence on substances other than alcohol or\n             nicotine.\n\n          -  Current use of disulfiram.\n\n          -  Psychotic or otherwise severely psychiatrically disabled.\n\n          -  Use of other psychotropic medications including antidepressants and anxiolytics.\n\n          -  Medical conditions that would not permit the use of sertraline or naltrexone, such as\n             a history of unstable or severe hepatic, cardiovascular, metabolic, endocrine,\n             gastrointestinal or kidney disease.\n\n          -  Hepatocellular disease or elevated bilirubin levels.\n\n          -  Females who are pregnant, nursing, or not using a reliable method of birth control.\n\n          -  Probation or parole requirements that might interfere with participation in the\n             study.\n\n          -  Involvement in alcohol treatment other than provided by the study or AA.\n\n          -  Use of monoamine oxidase inhibitors in the past month.\n\n          -  Current use of Type 1C antiarrhythmics propafenone and flecainide."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "198", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000451", 
            "org_study_id": "NIAAAOMA12028", 
            "secondary_id": "R01AA012028"
        }, 
        "intervention": [
            {
                "arm_group_label": "2", 
                "description": "16 week outpatient study", 
                "intervention_name": "sertraline", 
                "intervention_type": "Drug", 
                "other_name": "Zoloft"
            }, 
            {
                "arm_group_label": [
                    "1", 
                    "2"
                ], 
                "description": "16 week outpatient study", 
                "intervention_name": "naltrexone", 
                "intervention_type": "Drug", 
                "other_name": "Revia"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naltrexone", 
                "Sertraline"
            ]
        }, 
        "keyword": [
            "Alcoholism", 
            "Alcohol Dependence"
        ], 
        "lastchanged_date": "January 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Naltrexone and SSRI Therapy for Alcohol Dependence in Alaska Natives", 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Dr. Stephanie O'Malley", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Days abstinent"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000451"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2003", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "null": "41.308 -72.928"
    }
}